Teva Sues Perrigo, Catalent to Halt ANDA Plans for Asthma Drug
Teva is suing Perrigo and Catalent Pharma Solutions to stop the companies’ plans to market and develop generic versions of its asthma drug ProAir HFA before two key patents pop.
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.